Rheumatology Department and IDISSC, La Fundacion para la Investigacion Biomedica del Hospital Clinico San Carlos, Madrid, Spain.
Rheumatology Department and IDISSC, La Fundacion para la Investigacion Biomedica del Hospital Clinico San Carlos, Madrid, Spain
Ann Rheum Dis. 2020 Nov;79(11):1393-1399. doi: 10.1136/annrheumdis-2020-217984. Epub 2020 Aug 7.
To describe patients with autoimmune inflammatory rheumatic diseases (AIRD) who had COVID-19 disease; to compare patients who required hospital admission with those who did not and assess risk factors for hospital admission related to COVID-19.
An observational longitudinal study was conducted during the pandemic peak of severe acute respiratory syndrome coronavirus 2 (1 March 2020 to 24 April). All patients attended at the rheumatology outpatient clinic of a tertiary hospital in Madrid, Spain with a medical diagnosis of AIRD and with symptomatic COVID-19 were included. The main outcome was hospital admission related to COVID-19. The covariates were sociodemographic, clinical and treatments. We ran a multivariable logistic regression model to assess risk factors for the hospital admission.
The study population included 123 patients with AIRD and COVID-19. Of these, 54 patients required hospital admission related to COVID-19. The mean age on admission was 69.7 (15.7) years, and the median time from onset of symptoms to hospital admission was 5 (3-10) days. The median length of stay was 9 (6-14) days. A total of 12 patients died (22%) during admission. Compared with outpatients, the factors independently associated with hospital admission were older age (OR: 1.08; p=0.00) and autoimmune systemic condition (vs chronic inflammatory arthritis) (OR: 3.55; p=0.01). No statistically significant findings for exposure to disease-modifying antirheumatic drugs were found in the final model.
Our results suggest that age and having a systemic autoimmune condition increased the risk of hospital admission, whereas disease-modifying antirheumatic drugs were not associated with hospital admission.
描述患有自身免疫性炎症性风湿病(AIRD)合并 COVID-19 的患者;比较需要住院治疗的患者与无需住院治疗的患者,并评估与 COVID-19 相关的住院风险因素。
这是一项在严重急性呼吸综合征冠状病毒 2 流行高峰期(2020 年 3 月 1 日至 4 月 24 日)进行的观察性纵向研究。所有在西班牙马德里一家三级医院风湿科门诊就诊且被诊断为 AIRD 并伴有症状性 COVID-19 的患者均被纳入本研究。主要结局为与 COVID-19 相关的住院治疗。协变量为社会人口学、临床和治疗。我们进行了多变量逻辑回归模型以评估住院的风险因素。
该研究人群包括 123 例患有 AIRD 和 COVID-19 的患者。其中,54 例患者因 COVID-19 需要住院治疗。入院时的平均年龄为 69.7(15.7)岁,从症状出现到住院的中位时间为 5(3-10)天。中位住院时间为 9(6-14)天。共有 12 例患者在住院期间死亡(22%)。与门诊患者相比,与住院相关的独立因素为年龄较大(OR:1.08;p=0.00)和自身免疫性系统性疾病(与慢性炎症性关节炎相比)(OR:3.55;p=0.01)。最终模型中未发现疾病修饰抗风湿药物暴露与住院之间存在统计学显著关系。
我们的研究结果表明,年龄和自身免疫性系统性疾病增加了住院的风险,而疾病修饰抗风湿药物与住院无关。